Michael J. Fox Foundation
Grifols Secures $21M MJFF Grant to Search for Early Parkinson's Biomarkers
Grifols subsidiary Alkahest will lead a pilot study to track proteomic changes in patient plasma samples over a 10-year period.
Alamar Biosciences, Michael J. Fox Foundation Partner on Parkinson's Research
The partners will use Alamar's NULISA proteomics platform to develop assays for identifying biomarkers linked to neuronal synuclein diseases including Parkinson's.
Michael J. Fox Foundation Launches Initiative to Support Development of LRRK2-Targeted Therapies
The LRRK2 Investigative Therapeutics Exchange aims to advance basic sciences and support development of new drugs and LRRK2-specific biomarkers.
The letter encourages drug developers to "further study and use" αSyn-SAA testing for selecting patients for clinical trials for Parkinson's and related diseases.
Foundation for the NIH Launches $21M Research Project to Identify Parkinson's Disease Biomarkers
The new public-private partnership is funded by organizations including the NIH, FDA, Michael J. Fox Foundation, C2N Diagnostics, and Sanofi.
Mar 27, 2024